The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties.

The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties.

Cytogenetics is considered one of the most valuable prognostic determinants in acute myeloid leukemia (AML). However, many studies on which this assertion is based were limited by relatively small sample sizes or varying treatment approach, leading to conflicting data regarding the prognostic implic...

Full description

Bibliographic Details
Main Authors:	Grimwade, D, Walker, H, Oliver, F, Wheatley, K, Harrison, C, Harrison, G, Rees, J, Hann, I, Stevens, R, Burnett, A, Goldstone, A
Format:	Journal article
Language:	English
Published:	1998

Similar Items

Impact of diagnostic cytogenetics on outcome in AML: Analysis of 1,613 patients entered into the UK MRC AML 10 trial.
by: Grimwade, D, et al.
Published: (1996)

The importance of diagnostic cytogenetics in older patients with AML: Analysis of 922 patients entered into the MRC AML 11 trial.
by: Grimwade, D, et al.
Published: (1999)

Del(9q) AML: Clinical, cytological and cytogenetic characteristics and prognostic implications for patients entering the MRC AML trials.
by: Peniket, A, et al.
Published: (1999)

Outcome for children with relapsed acute myeloid leukaemia following initial therapy in the Medical Research Council (MRC) AML 10 trial. MRC Childhood Leukaemia Working Party.
by: Webb, D, et al.
Published: (1999)

The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial.
by: Grimwade, D, et al.
Published: (2001)

A simple, robust and highly predictive prognostic index for the determination of risk directed therapy in acute myeloid leukaemia (AML) derived from the United Kingdom medical research council (MRC) AML10 trial.
by: Wheatley, K, et al.
Published: (1995)

The value of allogeneic bone marrow transplant in patients with acute myeloid leukaemia at differing risk of relapse: results of the UK MRC AML 10 trial.
by: Burnett, A, et al.
Published: (2002)

Clinical features, cytogenetics and outcome in acute lymphoblastic and myeloid leukaemia of infancy: report from the MRC Childhood Leukaemia working party.
by: Chessells, J, et al.
Published: (2002)

The presence of a FLT3 mutation in AML adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: Analysis of 854 patients from the MRC AML 10 and 12 trials.
by: Kottaridis, P, et al.
Published: (2000)

Adverse impact of bone marrow transplantation on quality of life in acute myeloid leukaemia patients; analysis of the UK Medical Research Council AML 10 Trial.
by: Watson, M, et al.
Published: (2004)

Cytogenetics adds independent prognostic information in adults with acute lymphoblastic leukaemia on MRC trial UKALL XA. MRC Adult Leukaemia Working Party.
by: Secker-Walker, L, et al.
Published: (1997)

Cytogenetics and prognosis in childhood lymphoblastic leukaemia: results of MRC UKALL X. Medical Research Council Working Party in Childhood Leukaemia.
by: Chessels, J, et al.
Published: (1997)

AML associated with previous cytotoxic therapy, MDS or myeloproliferative disorders: results from the MRC's 9th AML trial.
by: Hoyle, C, et al.
Published: (1989)

Severe adverse impact on sexual functioning and fertility of bone marrow transplantation, either allogeneic or autologous, compared with consolidation chemotherapy alone: analysis of the MRC AML 10 trial.
by: Watson, M, et al.
Published: (1999)

Continuing (maintenance) therapy in lymphoblastic leukaemia: lessons from MRC UKALL X. Medical Research Council Working Party in Childhood Leukaemia.
by: Chessells, J, et al.
Published: (1997)

The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials.
by: Kottaridis, P, et al.
Published: (2001)

Detection of minimal residual disease (MRD) in APL by "real-time" RT-PCR: Analysis of cases entered into the UK MRC ATRA trial.
by: Grimwade, D, et al.
Published: (1999)

Analysis of the immunophenotype of children treated on the Medical Research Council United Kingdom Acute Lymphoblastic Leukaemia Trial XI (MRC UKALLXI). Medical Research Council Childhood Leukaemia Working Party.
by: Hann, I, et al.
Published: (1998)

TEL-AML1 fusion in childhood acute lymphoblastic leukaemia (ALL): Demographics, clinical features, cytogenetic characteristics and prognosis
by: Moorman, A, et al.
Published: (2005)

Benefit of intensified treatment for all children with acute lymphoblastic leukaemia: results from MRC UKALL XI and MRC ALL97 randomised trials. UK Medical Research Council's Working Party on Childhood Leukaemia.
by: Hann, I, et al.
Published: (2000)

Optical Genome Mapping for Cytogenetic Diagnostics in AML
by: Verena Nilius-Eliliwi, et al.
Published: (2023-03-01)

Relationships between age at diagnosis, clinical features and outcome of therapy in children treated in the Medical Research Council trials for acute myeloid leukemia AML 10 and 12.
by: Webb, D, et al.
Published: (2000)

Relationships between age at diagnosis, clinical features, and outcome of therapy in children treated in the Medical Research Council AML 10 and 12 trials for acute myeloid leukemia.
by: Webb, D, et al.
Published: (2001)

Del (9q) AML: clinical and cytological characteristics and prognostic implications.
by: Peniket, A, et al.
Published: (2005)

Comparison of allogeneic transplant versus chemotherapy for relapsed childhood acute lymphoblastic leukaemia in the MRC UKALL R1 trial. MRC Childhood Leukaemia Working Party.
by: Harrison, G, et al.
Published: (2000)

Treatment of high risk leukaemia - Results of MRC childhood acute lymphoblastic leukaemia study MRC HR-1.
by: Kinsey, S, et al.
Published: (2002)

The role of molecular diagnosis and residual disease monitoring in APL: Results of the MRC ATRA trial.
by: Grimwade, D, et al.
Published: (1998)

Clinical relevance of failed and missing cytogenetic analysis in acute myeloid leukaemia
by: Chilton, L, et al.
Published: (2017)

Acute lymphoblastic leukaemia in infancy: experience in MRC UKALL trials. Report from the Medical Research Council Working Party on Childhood Leukaemia.
by: Chessells, J, et al.
Published: (1994)

Differential Analysis of Genetic, Epigenetic, and Cytogenetic Abnormalities in AML
by: Islam, M., et al.
Published: (2017)

Karyotype is an independent prognostic factor in adult acute lymphoblastic leukaemia (ALL): Analysis of cytogenetic data from 1,235 patients on the medical research council (MRC) UKALLXII/Eastern cooperative oncology group (ECOG) 2993 trial.
by: Moorman, A, et al.
Published: (2005)

MicroRNAs distinguish cytogenetic subgroups in pediatric AML and contribute to complex regulatory networks in AML-relevant pathways.
by: Svenja Daschkey, et al.
Published: (2013-01-01)

Prognostic Relevance of Cytogenetics in Childhood Acute Lymphoblastic Leukaemia (ALL): Final Results From MRC ALL97.
by: Moor-Man, A, et al.
Published: (2009)

Association between reproducible flow cytometric methodology for measuring multidrug resistance and remission rates in AML
by: Pallis, M, et al.
Published: (1998)

DNA Methylation Clusters and Their Relation to Cytogenetic Features in Pediatric AML
by: Jatinder K. Lamba, et al.
Published: (2020-10-01)

EVI1 expression in acute myeloid leukaemia.
by: Langabeer, SE, et al.
Published: (2001)

High bax expression modulates response to treatment and survival in AML.
by: Truran, L, et al.
Published: (1999)

Long-term follow-up of the United Kingdom Medical Research Council protocols for childhood acute lymphoblastic leukaemia, 1980-1997. Medical Research Council Childhood Leukaemia Working Party.
by: Eden, O, et al.
Published: (2000)

No evidence that CD33 splicing SNP impacts the response to GO in younger adults with AML treated on UK MRC/NCRI trials
by: Gale, R, et al.
Published: (2018)

Acute Myeloid Leukaemia (AML) Presenting as a Bilateral Pleural Effusion
by: Ranjan Agrawal
Published: (2013-01-01)